Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 5/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738818 | 0.79 | HTR2C (0.37) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL1738817 | 0.79 | HTR2C (0.37) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL13999774 | 0.78 | SIGMAR1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL11019666 | 0.78 | SIGMAR1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649513 | 0.77 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649520 | 0.77 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL5568863 | 0.77 | HDAC1 (0.47) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL7649510 | 0.77 | PIM1 (0.42) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL3544732 | 0.77 | HTR2C (0.41) | HTR2CHTR2BHTR2ASIGMAR1HDAC1 | |
| SCHEMBL15533224 | 0.76 | ALDH1A1 (0.45) | HTR2CHDAC1PIM1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727794-B1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PROD INC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263484-A1 | SINGLE CHAIN FC TYPE III INTERFERONS AND METHODS OF USING SAME | ZYMOGENETICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-7479559-B2 | 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation | PFIZER INC. (US) | 2009-01-20 | — | — | US | disclosed |
| CN-1934081-A | Novel benayl(idene)-lactam derivatives | PFIZER (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1727794-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | Pfizer Products Incorporated (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005090300-A1 | NOVEL BENZYL(IDENE)-LACTAM DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | HTR2C 13/4885HTR2B 11/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.